Programmed-death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown promising results in recent clinical trials in metastatic renal cell carcinoma (mRCC), according to data presented at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting.
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Findings of recently completed trials have shown that atezolizumab and pembrolizumab could be possible first-line therapy options for cisplatin-ineligible patients with advanced and metastatic urothelial carcinoma, according to a presentation at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting 2018.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.